Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dr. Jost PH DRENTH, MD, Ph.D
National Coordinator - UMC St Radboud Nijmegen - Nijmegen - The Netherlands
Principal Investigator - Dr. Sven FRANCQUE, M.D.
National Coordinator - UZA - Edegem - Belgium
Principal Investigator - Pr. Arun SANYAL, M.D.
National Coordinator -Virginia Commonwealth University - Richmond - USA
Principal InvestigatorKOL profile → - Pr. Elisabetha BUGIANESI, M.D.
National Coordinator - University of Torino - S. Giovanni Battista Hospital - Torino - Italy
Principal Investigator - Pr. Manuel ROMERO-GOMEZ, M.D.
National Coordinator - Valme University hospital - Sevilla - Spain
Principal Investigator - Pr. Michael Manns, M.D.
National Coordinator - Medical School of Hannover - Hannover - Germany
Principal Investigator - Pr. Mihai VOICULESCU, M.D.
National Coordinator - Center of Internal Medicine, Fundeni Clinical Institute - Bucharest - Romania
Principal Investigator - Pr. Quentin M. ANSTEE, M.D.
National Coordinator - Freeman Hospital - Newcastle - UK
Principal Investigator - Pr. Vlad RATZIU, M.D.
International Coordinator - La Pitié-Salpêtrière Hospital - Paris 13, France
Study Chair - Rémy HANF, PhD
Development Director Genfit, France
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
56 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 205
Brussels, Belgium
- Site 201
Edegem, Belgium
- Site 204
Ghent, Belgium
- Site 202
Haine-Saint-Paul, Belgium
- Site 203
Leuven, Belgium
- Site 106
Amiens, France
- Site 102
Angers, France
- Site 114
Clichy, France
- Site 103
Lille, France
- Site 113
Lyon, France
- Site 111
Marseille, France
- Site 108
Montpellier, France
- Site 104
Nantes, France
- Site 109
Nice, France
- Site 101
Paris, France
- Site 112
Paris, France
- Site 107
Pessac, France
- Site 405
Bonn, Germany
- Site 404
Mainz, Germany
- Site 507
Milan, Italy
- Site 503
Palermo, Italy
- Site 504
Roma, Italy
- Site 501
Torino, Italy
- Site 303
Amsterdam, Netherlands
- Site 302
Nijmegen, Netherlands
- Site 601
Bucharest, Romania
- Site 602
Bucharest, Romania
- Site 603
Bucharest, Romania
- Site 703
Barcelona, Spain
- Site 707
Majadahonda, Spain
- Site 705
Málaga, Spain
- Site 706
Santander, Spain
- Site 701
Seville, Spain
- Site 802
Camberley, United Kingdom
- Site 808
Hull, United Kingdom
- Site 801
Newcastle upon Tyne, United Kingdom
- Site 803
Nottingham, United Kingdom
- Site 920
Fresno, California, United States
- Site 903
La Jolla, California, United States
- Site 911
Aurora, Colorado, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 28 Feb 2015
- Completion
- 31 Dec 2015
- Last update posted
- 3 Nov 2022
- Registered enrollment
- 275
- Registry id
- NCT01694849
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.